• What is the relative efficacy of different pharmacological augmentation and combination strategies, and what is their efficacy compared with treatment with single agents?
  • How does the presence of certain clinical features (for example, prominent self-destructive behavior or dissociative features) affect response to pharmacotherapy?
  • What is the minimal dose and duration of an adequate trial for different medications in patients with borderline personality disorder?
  • What is the optimal duration of different types of medication treatment?
  • What are the indications for discontinuation of effective pharmacological treatment?
  • Are atypical neuroleptics or typical neuroleptics more effective or better tolerated in patients with borderline personality disorder?
  • How efficacious are mood stabilizers for patients with borderline personality disorder, and which patients are most likely to benefit from this treatment? Are certain mood stabilizers more effective than others?
  • What role should ECT have in the treatment of patients with refractory or severe borderline personality disorder?

Appendixes:


Psychopharmacological Treatment Algorithms

Appendix 1

  • Psychopharmacological Treatment of Affective Dysregulation Symptoms in Patients With Borderline Personality Disordera

    • ͺAlgorithm based on clinical judgment that uses evidence currently in the literature, following the format of the International Psychopharmacology Algorithm Project (2). The first step in the algorithm is generally supported by the best empirical evidence. Recommendations may not be applicable to all patients or take individual needs into account. The empirical research studies on which these recommendations are based may be "first trials" involving previously untreated patients and may not take into account previous patient nonresponse to one, two, or even three levels of the algorithm (i.e., patients who, by definition, have more refractory disorders). There are no empirical trials of the complete algorithm.

    Appendix 2

    Psychopharmacological Treatment of Impulsive-Behavioral Dyscontrol Symptoms in Patients With Borderline Personality Disordera

    ͺAlgorithm based on clinical judgment that uses evidence currently in the literature, following the format of the International Psychopharmacology Algorithm Project (2). The first step in the algorithm is generally supported by the best empirical evidence. Recommendations may not be applicable to all patients or take individual needs into account. The empirical research studies on which these recommendations are based may be "first trials" involving previously untreated patients and may not take into account previous patient nonresponse to one, two, or even three levels of the algorithm (i.e., patients who, by definition, have more refractory disorders). There are no empirical trials of the complete algorithm.

    bSSRI treatment must be discontinued and followed with an adequate washout period before initiating treatment with an MAOI.

     

    Appendix 3

    Psychopharmacological Treatment of Cognitive-Perceptual Symptoms in Patients With Borderline Personality Disorderͺ

    ͺAlgorithm based on clinical judgment that uses evidence currently in the literature, following the format of the International Psychopharmacology Algorithm Project (2). The first step in the algorithm is generally supported by the best empirical evidence. Recommendations may not be applicable to all patients or take individual needs into account. The empirical research studies on which these recommendations are based may be "first trials" involving previously untreated patients and may not take into account previous patient nonresponse to one, two, or even three levels of the algorithm (i.e., patients who, by definition, have more refractory disorders). There are no empirical trials of the complete algorithm.

    bThe generally favorable side effect profiles of the newer atypical neuroleptic medications compared with those of conventional neuroleptics underscore the need for careful empirical trials of these newer medications in the treatment of patients with borderline personality disorder.

     

    INDIVIDUALS AND ORGANIZATIONS THAT SUBMITTED COMMENTS

     

    Gerald Adler, M.D.

    Hagop Akiskal, M.D.

    Deborah Antai-Otong, M.S., R.N., P.M.H.N.P., C.S.

    Lorna Benjamin, Ph.D.

    Sandra Smith Bjork, R.N., J.D.

    Nashaat N. Boutros, M.D.

    Daniel Buie, M.D.

    Kenneth Busch, M.D.

    Carlyle H. Chan, M.D.

    Richard D. Chessick, M.D., Ph.D.

    Diego Cohen, M.D.

    Nancy Collins, R.N., M.P.H.

    Alv A. Dahl, M.D.

    Dave M. Davis, M.D.

    Diana Dell, M.D.

    Anita S. Everett, M.D.

    Robert Findling, M.D.

    Douglas H. Finestone, M.D.

    Arnold Goldberg, M.D.

    William M. Greenberg, M.D.

    Elliot A. Harris, M.D.

    Al Herzog, M.D.

    Eric Hollander, M.D.

    Patricia Hoffman Judd, Ph.D.

    Morten Kjolbye, M.D.

    Ronald Koegler, M.D.

    Paul S. Links, M.D.

    Cesare Maffei, M.D.

    Paul Markovitz, M.D., Ph.D.

    John C. Markowitz, M.D.

    James F. Masterson, M.D.

    William Meissner, M.D.

    Mary D. Moller, M.S.N., C.S., P.M.H.N.P.

    Robert Michels, M.D.

    Richard Munich, M.D.

    Nathan A. Munn, M.D.

    Andrei Novac, M.D.

    Stefano Pallanti, M.D.

    Joel Paris, M.D.

    Jane L. Pearson, Ph.D.

    Gary Peterson, M.D.

    Eric M. Plakun, M.D.

    Charles W. Portney, M.D.

    Lawrence H. Rockland, M.D.

    Barbara Rosenfeld, M.D.

    Marc Rothman, M.D.

    Marian Scheinholtz, M.S., O.T.R.L.

    Judy Sigmund, M.D.

    Kenneth R. Silk, M.D.

    Andrew E. Skodol, M.D.

    Robert Stern, M.D., Ph.D.

    Nada L. Stotland, M.D., M.P.H.

    Richard T. Suchinsky, M.D.

    Peter J. Sukin, M.D.

    Arthur Summer, M.D.

    Marijo Tamburrino, M.D.

    William R. Tatomer, M.D.

    Per Vaglum, M.D.

    Robert S. Wallerstein, M.D.

    Sidney Weissman, M.D.

    Drew Westen, Ph.D.

    Jerome Winer, M.D.

    American Academy of Ophthalmology

    American College of Obstetrics and Gynecology

    American College of Radiology

    American Occupational Therapy Association

    American Psychiatric Nurses Association

    American Psychoanalytic Association

    Commonwealth of Virginia Department of Mental Health, Mental Retardation and Substance Abuse Services

    Illinois Psychiatric Society

    International Society for the Study of Personality Disorders

    New Jersey Psychiatric Association

    Norwegian Psychiatric Association

    Royal Australian and New Zealand College of Psychiatrists

    References

    The following coding system is used to indicate the nature of the supporting evidence in the references:

    [A] Randomized clinical trial. A study of an intervention in which subjects are prospectively followed over time; there are treatment and control groups; subjects are randomly assigned to the two groups; both the subjects and the investigators are blind to the assignments.

    [B] Clinical trial. A prospective study in which an intervention is made and the results of that intervention are tracked longitudinally; study does not meet standards for a randomized clinical trial.

    [C] Cohort or longitudinal study. A study in which subjects are prospectively followed over time without any specific intervention.

    [D] Case-control study. A study in which a group of patients and a group of control subjects are identified in the present and information about them is pursued retrospectively or backward in time.

    [E] Review with secondary data analysis. A structured analytic review of existing data, e.g., a meta-analysis or a decision analysis.

    [F] Review. A qualitative review and discussion of previously published literature without a quantitative synthesis of the data.

    [G] Other. Textbooks, expert opinion, case reports, and other reports not included above.

    1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed, Text Revision (DSM-IV-TR). Washington, DC, APA, 2000 [G]

    2. Jobson KO, Potter WZ: International Psychopharmacology Algorithm Project report. Psychopharmacol Bull 1995; 31:457–507 [F]

    3. American Psychiatric Association: Practice Guideline for Psychiatric Evaluation of Adults. Am J Psychiatry 1995; 152(Nov suppl) [G]

    4. Kernberg OF, Selzer M, Koenigsberg H, Carr A, Appelbaum A: Psychodynamic Psychotherapy of Borderline Patients. New York, Basic Books, 1989 [G]

    5. Linehan MM, Heard HL, Armstrong HE: Naturalistic follow-up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993; 50:971–974; correction, 1994; 51:422 [A]

    6. Kjelsberg E, Eikeseth PH, Dahl AA: Suicide in borderline patients—predictive factors. Acta Psychiatr Scand 1991; 84:283–287 [D]

    7. Sederer LI, Ellison J, Keyes C: Guidelines for prescribing psychiatrists in consultative, collaborative, and supervisory relationships. Psychiatr Serv 1998; 49:1197–1202 [F]

    8. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL: Cognitive-behavioral treatment of chronically parasuicidal borderline patients. Arch Gen Psychiatry 1991; 48: 1060–1064 [A]

    9. Bateman A, Fonagy P: Effectiveness of partial hospitalization in the treatment of borderline personality disorder: a randomized controlled trial. Am J Psychiatry 1999; 156: 1563–1569 [A]

    10. Bateman A, Fonagy P: Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 2001; 158:36–42 [A]

    11. Gabbard GO, Horwitz L, Allen JG, Frieswyk S, Newsom G, Colson DB, Coyne L: Transference interpretation in the psychotherapy of borderline patients: a high-risk, high-gain phenomenon. Harv Rev Psychiatry 1994; 2:59–69 [B]

    12. Gunderson JG: Borderline Personality Disorder: A Clinical Guide. Washington, DC, American Psychiatric Press, 2001 [G]

    13. Clarkin JF, Yeomans FE, Kernberg OF: Psychotherapy for Borderline Personality. New York, John Wiley & Sons, 1999 [G]

    14. Adler G: Borderline Psychopathology and Its Treatment. New York, Jason Aronson, 1985 [G]

    15. Gabbard GO, Wilkinson SM: Management of Countertransference With Borderline Patients. Washington, DC, American Psychiatric Press, 1994 [G]

    16. Horwitz L, Gabbard GO, Allen JG: Borderline Personality Disorder: Tailoring the Psychotherapy to the Patient. Washington, DC, American Psychiatric Press, 1996 [B]

    17. Linehan MM: Cognitive-Behavioral Treatment of Borderline Personality Disorder. New York, Guilford Press, 1993 [G]

    18. Waldinger RJ: Intensive psychodynamic therapy with borderline patients: an overview. Am J Psychiatry 1987; 144:267–274 [G]

    19. Beck AT, Freeman AM: Cognitive Therapy of Personality Disorders. New York, Guilford Press, 1990 [G]

    20. Stevenson J, Meares R: An outcome study of psychotherapy for patients with borderline personality disorder. Am J Psychiatry 1992; 149:358–362 [B]

    21. Meares R, Stevenson J, Comerford A: Psychotherapy with borderline patients, I: a comparison between treated and untreated cohorts. Aust N Z J Psychiatry 1999; 33:467–472 [B]

    22. Boyer LB: Working with a borderline patient. Psychoanal Q 1977; 46:386–424 [G]

    23. Chessick RD: Intensive Psychotherapy of the Borderline Patient. New York, Jason Aronson, 1977 [G]

    24. Grotstein JS: The analysis of a borderline patient, in Technical Factors in the Treatment of the Severely Disturbed Patient. Edited by Giovacchini PL, Boyer LB. New York, Jason Aronson, 1982, pp 261–288 [G]

    25. Grotstein JS, Solomon MF, Lang JA: The Borderline Patient: Emerging Concepts in Diagnosis, Psychodynamics, and Treatment. Hillsdale, NJ, Analytic Press, 1987 [G]

    26. Gunderson JG: Borderline Personality Disorder. Washington, DC, American Psychiatric Press, 1984

    27. Kernberg OF: Borderline Conditions and Pathological Narcissism. New York, Jason Aronson, 1975 [G]

    28. Kernberg OF: Severe Personality Disorders: Psychotherapeutic Strategies. New Haven, Conn, Yale University Press, 1984 [G]

    29. Masterson JF: Psychotherapy of the Borderline Adult: A Developmental Approach. New York, Brunner/Mazel, 1976 [G]

    30. Masterson JF: The Personality Disorders: A New Look at the Developmental Self and Object Relations Approach. Phoenix, Ariz, Zeig, Tucker, 2000 [G]

    31. Meares R: Metaphor of Play: Disruption and Restoration in the Borderline Experience. Northvale, NJ, Jason Aronson, 1993 [G]

    32. Meares R: Intimacy and Alienation: Memory, Trauma, and Personal Being. New York, Routledge, 2000 [G]

    33. Meissner WW: The Borderline Spectrum: Differential Diagnosis and Developmental Issues. New York, Jason Aronson, 1984 [G]

    34. Meissner WW: Treatment of Patients in the Borderline Spectrum. Northvale, NJ, Jason Aronson, 1988 [G]

    35. Rinsley DB: Developmental Pathogenesis and Treatment of Borderline and Narcissistic Personalities. Northvale, NJ, Jason Aronson, 1989 [G]

    36. Searles HF: My Work With Borderline Patients. Northvale, NJ, Jason Aronson, 1986 [G]

    37. Stone MH: The Borderline Syndromes: Constitution, Personality, and Adaptation. New York, McGraw-Hill, 1980 [G]

    38. Waldinger RJ, Gunderson JG: Effective Psychotherapy With Borderline Patients: Case Studies. Washington, DC, American Psychiatric Press, 1987 [D]

    39. Abend SM, Porder MS, Willick MS: Borderline Patients: Psychoanalytic Perspectives. Madison, Conn, International Universities Press, 1983 [G]

    40. McGlashan TH: The Chestnut Lodge follow-up study, III: long-term outcome of borderline personalities. Arch Gen Psychiatry 1986; 43:20–30 [C]

    41. Seeman M, Edwardes-Evans B: Marital therapy with borderline patients: is it beneficial? J Clin Psychiatry 1979; 40:308–312 [G]

    42. Shapiro ER: Family dynamics and borderline personality disorder, in Handbook of Borderline Disorders. Edited by Silver D, Rosenbluth M. Madison, Conn, International Universities Press, 1992, pp 471–493 [G]

    43. Siever LJ, Trestman R: The serotonin system and aggressive personality disorder. Int Clin Psychopharmacol 1993; 8:33–39 [F]

    44. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E: Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15:23–29 [A]

    45. Markovitz P: Pharmacotherapy of impulsivity, aggression, and related disorders, in Impulsivity and Aggression. Edited by Hollander E, Stein DJ. New York, John Wiley & Sons, 1995, pp 263–287 [B]

    46. Cornelius JR, Soloff PH, Perel JM, Ulrich RF: Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151–154 [B]

    47. Kavoussi RJ, Liu J, Coccaro EF: An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55:137–141 [B]

    48. Markovitz PJ, Calabrese JR, Charles SC, Meltzer HY: Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148:1064–1067 [B]

    49. Norden MJ: Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13:885–893 [G]

    50. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM: Progress in pharmacotherapy of borderline disorders: a double-blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 1986; 43:691–697 [A]

    51. Soloff PH, George A, Nathan S, Schulz PM, Cornelius JR, Herring J, Perel JM: Amitriptyline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol 1989; 9:238–246 [A]

    52. Faltus FJ: The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 1984; 141:802–803 [G]

    53. Gardner DL, Cowdry RW: Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142:98–100 [A]

    54. Freinhar JP, Alvarez WA: Clonazepam: a novel therapeutic adjunct. Int J Psychiatry Med 1985; 15:321–328 [G]

    55. Cowdry RW, Gardner DL: Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry 1988; 45:111–119 [A]

    56. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF: Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50:377– 385 [A]

    57. Parsons B, Quitkin FM, McGrath PJ, Stewart JW, Tricamo E, Ocepek-Welikson K, Harrison W, Rabkin JG, Wager SG, Nunes E: Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol Bull 1989; 25:524–534 [A]

    58. Sheard MH: Lithium in the treatment of aggression. J Nerv Ment Dis 1975; 160:108–118 [B]

    59. Sheard MH, Marini JL, Bridges CI, Wagner E: The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry 1976; 133:1409–1413 [A]

    60. Tupin JP, Smith DB, Clanon TL, Kim LI, Nugent A, Groupe A: The long-term use of lithium in aggressive prisoners. Compr Psychiatry 1973; 14:311–317 [B]

    61. Links P, Steiner M, Boiago I, Irwin D: Lithium therapy for borderline patients: preliminary findings. J Personal Disord 1990; 4:173–181 [A]

    62. Gardner DL, Cowdry RW: Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 1986; 143:519–522 [A]

    63. De la Fuente J, Lotstra F: A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994; 4:479–486 [A]

    64. Gardner DL, Cowdry RW: Development of melancholia during carbamazepine treatment in borderline personality disorder. J Clin Psychopharmacol 1986; 6:236–239 [A]

    65. Hollander E, Allen A, Lopez RP, Bienstock C, Grossman R, Siever L, Margolin L, Stein D: A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62:199–203 [A]

    66. Stein DJ, Simeon D, Frenkel M, Islam MN, Hollander E: An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995; 56:506–510 [B]

    67. Coccaro EF, Kavoussi RJ: Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54:1081–1088 [A]

    68. Cornelius JR, Soloff PH, Perel JM, Ulrich RF: Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry 1993; 150:1843–1848 [A]

    69. Kavoussi RJ, Coccaro EF: Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59:676–680 [B]

    70. Wilcox J: Divalproex sodium in the treatment of aggressive behavior. Ann Clin Psychiatry 1994; 6:17–20 [B]

    71. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E: Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59:103–107 [B]

    72. Chengappa KN, Baker RW: The successful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder. J Personal Disord 1995; 9: 76–82 [G]

    73. Leone N: Response of borderline patients to loxapine and chlorpromazine. J Clin Psychiatry 1982; 43:148–150 [A]

    74. Serban G, Siegel S: Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984; 141:1455–1458 [A]

    75. Goldberg S, Schulz C, Schulz P, Resnick R, Hamer R, Friedel R: Borderline and schizotypal personality disorder treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 1986; 43:680–686 [A]

    76. Goldberg S: Prediction of change in borderline personality disorder. Psychopharmacol Bull 1989; 25:550–555 [E]

    77. Kutcher S, Papatheodorou G, Reiter S, Gardner D: The successful pharmacological treatment of adolescents and young adults with borderline personality disorder: a preliminary open trial of flupenthixol. J Psychiatry Neurosci 1995; 20:113–118 [B]

    78. Teicher M, Glod C, Aaronson S, Gunter P, Schatzberg A, Cole J: Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull 1989; 25:535–549 [B]

    79. Kelly T, Soloff PH, Cornelius JR, George A, Lis J: Can we study (treat) borderline patients: attrition from research and open treatment. J Personal Disord 1992; 6:417–433 [A]

    80. Montgomery SA, Montgomery D: Pharmacological prevention of suicidal behaviour. J Affect Disord 1982; 4:291–298 [A]

    81. Frankenburg F, Zanarini MC: Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34:402–405 [B]

    82. Schulz S, Camlin KL, Berry SA, Jesberger JA: Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429–1435 [B]

    83. Schulz SC, Camlin KL, Berry S, Friedman L: Risperidone for borderline personality disorder: a double blind study, in Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology. Nashville, Tenn, ACNP, 1999 [A]

    84. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Major Depressive Disorder (Revision). Am J Psychiatry 2000; 157(April suppl) [G]

    85. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994; 151(Dec suppl) [G]

    86. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Eating Disorders (Revision). Am J Psychiatry 2000; 157(Jan suppl) [G]

    87. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine, Opioids. Am J Psychiatry 1995; 152(Nov suppl) [G]

    88. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Panic Disorder. Am J Psychiatry 1998; 155(May suppl) [G]

    89. Soloff P, Cornelius J, George A: Relationship between axis I and axis II disorders: implications for treatment. Psychopharmacol Bull 1991; 27:23–30 [F]

    90. Soloff PH, George A, Nathan RS, Schulz PM: Characterizing depression in borderline patients. J Clin Psychiatry 1987; 48:155–157 [E]

    91. Rogers JH, Widiger TA, Krupp A: Aspects of depression associated with borderline personality disorder. Am J Psychiatry 1995; 152:268–270 [D]

    92. Gunderson JG, Phillips KA: A current view of the interface between borderline personality disorder and depression. Am J Psychiatry 1991; 148:967–975 [F]

    93. Stone MH: Abnormalities of Personality: Within and Beyond the Realm of Treatment. New York, WW Norton, 1993 [G]

    94. Losel F: Management of psychopaths, in Psychopathy: Theory, Research and Implications for Society. Edited by Cooke DJ, Forth AE, Hare RD. Boston, Kluwer, 1998, pp 303–354 [G]

    95. Dolan BM, Evans C, Wilson J: Therapeutic community treatment for personality disordered adults: changes in neurotic symptomatology on follow-up. Int J Soc Psychiatry 1992; 38:243–250 [B]

    96. Coccaro EF, Kavoussi RJ, Sheline YI, Lish JD, Csernansky JG: Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelet. Arch Gen Psychiatry 1996; 53:531–536 [G]

    97. Hare RD: The Hare Psychopathy Checklist—Revised. North Tonawanda, NY, Mental Health Systems, 1991 [G]

    98. Gunderson JG, Sabo AN: The phenomenological and conceptual interface between borderline personality disorder and PTSD. Am J Psychiatry 1993; 150:19–27 [F]

    99. Gunderson JG, Chu JA: Treatment implications of past trauma in borderline personality disorder. Harv Rev Psychiatry 1993; 1:75–81 [F]

    100. Paris J, Zweig-Frank H: Dissociation in patients with borderline personality disorder (letter). Am J Psychiatry 1997; 154:137–138 [F]

    101. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL: Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult Clin Psychol 1993; 61:984–991 [D]

    102. Davidson JR, Hughes D, Blazer DG, George LK: Post-traumatic stress disorder in the community: an epidemiological study. Psychol Med 1991; 21:713–721 [D]

    103. Ogata SN, Silk KR, Goodrich S, Lohr NE, Westen D, Hill EM: Childhood sexual and physical abuse in adult patients with borderline personality disorder. Am J Psychiatry 1990; 147:1008–1013 [D]

    104. Fossati A, Madeddu F, Maffei C: Borderline personality disorder and childhood sexual abuse: a meta-analytic study. J Personal Disord 1999; 13:268–280 [E]

    105. Lindemann E: Symptomatology and management of acute grief (1944). Am J Psychiatry 1994; 151(June suppl):155–160 [G]

    106. Spiegel D: Vietnam grief work using hypnosis. Am J Clin Hypn 1981; 24:33–40 [B]

    107. Butler LD, Duran REF, Jasiukaitis P, Kopan C, Spiegel D: Hypnotizability and traumatic experience: a diathesis-stress model of dissociative symptomatology (festschrift). Am J Psychiatry 1996; 153(July suppl):42–63 [F]

    108. Shapiro F: Eye movement desensitization and reprocessing (EMDR) and the anxiety disorders: clinical and research implications of an integrated psychotherapy treatment. J Anxiety Disord 1999; 13:35–67 [F]

    109. Wilson SA, Becker LA, Tinker RH: Eye movement desensitization and reprocessing (EMDR) treatment for psychologically traumatized individuals. J Consult Clin Psychol 1995; 63:928–937 [A]

    110. Wilson SA, Becker LA, Tinker RH: Fifteen-month follow-up of eye movement desensitization and reprocessing (EMDR) treatment for posttraumatic stress disorder and psychological trauma. J Consult Clin Psychol 1997; 65:1047–1056 [B]

    111. Jones B, Heard H, Startup M, Swales M, Williams JM, Jones RS: Autobiographical memory and dissociation in borderline personality disorder. Psychol Med 1999; 29:1397– 1404 [D]

    112. Chu JA, Dill DL: Dissociative symptoms in relation to childhood physical and sexual abuse. Am J Psychiatry 1990; 147:887–892 [D]

    113. Neisser U, Fivush R (eds): The Remembering Self: Construction and Accuracy in the Self-Narrative. New York, Cambridge University Press, 1994 [G]

    114. Saxe GN, van der Kolk BA, Berkowitz R, Chinman G, Hall K, Lieberg G, Schwartz J: Dissociative disorders in psychiatric inpatients. Am J Psychiatry 1993; 150:1037–1042 [D]

    115. Galletly C: Borderline-dissociation comorbidity (letter). Am J Psychiatry 1997; 154:1629 [G]

    116. Brodsky BS, Cloitre M, Dulit RA: Relationship of dissociation to self-mutilation and childhood abuse in borderline personality disorder. Am J Psychiatry 1995; 152:1788– 1792 [D]

    117. Ross CA, Miller SD, Reagor P, Bjornson L, Fraser GA, Anderson G: Structured interview data on 102 cases of multiple personality disorder from four centers. Am J Psychiatry 1990; 147:596–601 [D]

    118. Braun BG, Sacks RG: The development of multiple personality disorder: predisposing, precipitating, and perpetuating factors, in Childhood Antecedents of Multiple Personality. Edited by Kluft RP. Washington, DC, American Psychiatric Press, 1985, pp 37–64 [F]

    119. Kluft RP: The use of hypnosis with dissociative disorders. Psychiatr Med 1992; 10:31– 46 [F]

    120. Spiegel D, Maldonado J: Dissociative disorders, in The American Psychiatric Press Textbook of Psychiatry, 3rd ed. Edited by Hales RE, Yudofsky S, Talbott JA. Washington, DC, American Psychiatric Press, 1999, pp 711–737 [F]

    121. Spiegel D: Dissociative Disorders: A Clinical Review. Lutherville, Md, Sidran Press, 1996, pp 1156–1172 [G]

    122. Paris J, Zelkowitz P, Guzder J, Joseph S, Feldman R: Neuropsychological factors associated with borderline pathology in children. J Am Acad Child Adolesc Psychiatry 1999; 38:770–774 [D]

    123. Zanarini MC, Williams AA, Lewis RE, Reich RB, Vera SC, Marino MF, Levin A, Yong L, Frankenburg FR: Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry 1997; 154:1101–1106 [D]

    124. Paris J: The etiology of borderline personality disorder: a biopsychosocial approach. Psychiatry 1994; 57:316–325 [F]

    125. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J: Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153:592–606 [F]

    126. Cohen LS, Heller VL, Rosenbaum JF: Treatment guidelines for psychotropic drug use in pregnancy. Psychosomatics 1989; 30:25–33 [G]

    127. Cohen L: Approach to the patient with psychiatric disorders during pregnancy, in The MGH Guide to Psychiatry and Primary Care. New York, McGraw-Hill, 1998, pp 311–317 [F]

    128. Omtzigt JG, Los FJ, Grobbee DE, Pijpers L, Jahoda MG, Brandenburg H, Stewart PA, Gaillard HL, Sachs ES, Wladimiroff JW: The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42:119–125 [G]

    129. Loranger AW, Sartorius N, Andreoli A, Berger P, Buchheim P, Channabasavanna SM, Coid B, Dahl A, Diekstra RFW, Ferguson B, Jacobsberg LB, Mombour W, Pull C, Ono Y, Regier DA: The International Personality Disorder Examination: the World Health Organization/Alcohol, Drug Abuse, and Mental Health Administration International Pilot Study of Personality Disorders. Arch Gen Psychiatry 1994; 51:215–224 [B]

    130. Kissling W (ed): Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Berlin, Springer-Verlag, 1991 [G]

    131. Marcos LR, Cancro R: Pharmacotherapy of Hispanic depressed patients: clinical observations. Am J Psychother 1982; 36:505–512 [F]

    132. Escobar JI, Tuason VB: Antidepressant agents: a cross-cultural study. Psychopharmacol Bull 1980; 16:49–52 [F]

    133. Klein JI, Macbeth JE, Onek JN: Legal Issues in the Private Practice of Psychiatry. Washington, DC, American Psychiatric Press, 1994 [G]

    134. Paris J, Brown R, Nowlis D: Long-term follow-up of borderline patients in a general hospital. Compr Psychiatry 1987; 28:530–535 [D]

    135. Bender DS, Dolan RT, Skodol AE, Sanislow CA, Dyck IR, McGlashan TH, Shea MT, Zanarini MC, Oldham JM, Gunderson JG: Treatment utilization by patients with personality disorders. Am J Psychiatry 2001; 158:295–302 [C]

    136. Phillips KA, Gunderson JG: Personality disorders, in The American Psychiatric Press Textbook of Psychiatry, 3rd ed. Edited by Hales RE, Yudofsky SC, Talbott JA. Washington, DC, American Psychiatric Press, 1999, pp 795–823 [G]

    137. Stone MH: Long-Term Follow-Up Study of Borderline Patients: The Fate of Borderlines. New York, Guilford, 1990 [C]

    138. Stevenson J, Meares R: Psychotherapy with borderline patients, II: a preliminary cost benefit study. Aust N Z J Psychiatry 1999; 33:473–477 [B]

    139. Gabbard GO: Psychodynamic Psychiatry in Clinical Practice, 3rd ed. Washington, DC, American Psychiatric Press, 2000 [G]

    140. Clarkin JF, Yeomans F, Kernberg OF: Psychodynamic Psychotherapy of Borderline Personality Organization: A Treatment Manual. New York, John Wiley & Sons, 1998 [G]

    141. Wallerstein RW: Forty-Two Lives in Treatment. New York, Guilford, 1986 [D]

    142. Howard KI, Kopta SM, Krause MS, Orlinsky DE: The dose-effect relationship in psychotherapy. Am Psychol 1986; 41:159–164 [D]

    143. Gabbard GO: Borderline Personality Disorder and Rational Managed Care Policy. Psychoanal Inquiry Suppl 1997, pp 17–28 [G]

    144. Beck JS: Complex cognitive therapy treatment for personality disorder patients. Bull Menninger Clin 1998; 62:170–194 [G]

    145. Layden MA, Newman CF, Freeman A, Morse SB: Cognitive Therapy of Borderline Personality Disorder. Boston, Allyn & Bacon, 1993 [G]

    146. Millon T: On the genesis and prevalence of the borderline personality disorder: a social learning thesis. J Personal Disord 1987; 1:354–372 [G]

    147. Young JE: Cognitive Therapy for Personality Disorders: A Schema-Focused Approach. Sarasota, Fla, Professional Resource Exchange, 1990 [G]

    148. Linehan MM, Tutek DA, Heard HL, Armstrong HE: Interpersonal outcome of cognitive behavioral treatment for chronically suicidal borderline patients. Am J Psychiatry 1994; 151:1771–1776 [B]

    149. Linehan MM, Schmidt H III, Dimeff LA, Craft JC, Kanter J, Comtois KA: Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict 1999; 8:279–292 [A]

    150. Linehan MM, Heard HL: Impact of treatment accessibility on clinical course of parasuicidal patients (letter). Arch Gen Psychiatry 1993; 50:157–158 [G]

    151. Springer T, Lohr NE, Buchtel HA, Silk KR: A preliminary report of short-term cognitive-behavioral group therapy for inpatients with personality disorders. J Psychother Pract Res 1995; 5:57–71 [A]

    152. Barley W, Buie SE, Peterson EW, Hollingsworth A, Griva M, Hickerson S, Lawson J, Bailey B: Development of an inpatient cognitive-behavioral treatment program for borderline personality disorder. J Personal Disord 1993; 7:232–240 [B]

    153. Perris C: Cognitive therapy in the treatment of patients with borderline personality disorders. Acta Psychiatr Scand Suppl 1994; 379:69–72 [F]

    154. Liberman RP, Eckman T: Behavior therapy vs insight-oriented therapy for repeated suicide attempters. Arch Gen Psychiatry 1981; 38:1126–1130 [A]

    155. Salkovskis PM, Atha C, Storer D: Cognitive-behavioural problem solving in the treatment of patients who repeatedly attempt suicide: a controlled trial. Br J Psychiatry 1990; 157:871–876 [A]

    156. Evans K, Tyrer P, Catalan J, Schmidt U, Davidson K, Dent J, Tata P, Thornton S, Barber J, Thompson S: Manual-assisted cognitive-behaviour therapy (MACT): a randomized controlled trial of a brief intervention with bibliotherapy in the treatment of recurrent deliberate self-harm. Psychol Med 1999; 29:19–25 [A]

    157. Greene LR, Cole MB: Level and form of psychopathology and the structure of group therapy. Int J Group Psychother 1991; 41:499–521 [B]

    158. Hafner RJ, Holme G: The influence of a therapeutic community on psychiatric disorder. J Clin Psychol 1996; 52:461–468 [C]

    159. Goodwin JM, Wilson N, Connell V: Natural history of severe symptoms in borderline women treated in an incest group. Dissociation 1994; 5:221–226 [D]

    160. Marziali E, Munroe-Blum H, McCleary L: The contribution of group cohesion and group alliance to the outcome of group psychotherapy. Int J Group Psychother 1997; 47:475– 497 [A]

    161. Wilberg T, Friis S, Karterud S, Mehlum L, Urnes O, Vaglum P: Outpatient group psychotherapy: a valuable continuation treatment for patients with borderline personality disorder treated in a day hospital? a 3-year follow-up study. Nord Psykiatr Tidsskr 1998; 52:213–222 [B]

    162. Higgitt A, Fonagy P: Psychotherapy in borderline and narcissistic personality disorder. Br J Psychiatry 1992; 161:23–43 [F]

    163. Marziali E, Monroe-Blum H: Interpersonal Group Psychotherapy for Borderline Personality Disorder. New York, Basic Books, 1994 [A]

    164. Koch A, Ingram T: The treatment of borderline personality disorder within a distressed relationship. J Marital Fam Ther 1985; 11:373–380 [G]

    165. Weddige R: The hidden psychotherapeutic dilemma: spouse of the borderline. Am J Psychother 1986; 40:52–61 [G]

    166. McCormack C: The borderline/schizoid marriage: the holding environment as an essential treatment construct. J Marital Fam Ther 1989; 15:299–309 [G]

    167. Jones SA: Family therapy with borderline and narcissistic patients. Bull Menninger Clin 1987; 51:285–295 [G]

    168. Clarkin JF, Marziali E, Munroe-Blum H: Group and family treatments for borderline personality disorder. Hosp Community Psychiatry 1991; 42:1038–1043 [F]

    169. Villeneuve C, Roux N: Family therapy and some personality disorders in adolescence. Adolesc Psychiatry 1995; 20:365–380 [G]

    170. Gunderson JG, Berkowitz C, Ruiz-Sancho A: Families of borderline patients: a psychoeducational approach. Bull Menninger Clin 1997; 61:446–457 [G]

    171. Gunderson JG, Kerr J, Englund DW: The families of borderlines: a comparative study. Arch Gen Psychiatry 1980; 37:27–33 [D]

    172. Markovitz P, Wagner S: Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31:773–777 [B]

    173. Coccaro EF, Astill JL, Herbert JL, Schut AG: Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients (letter). J Clin Psychopharmacol 1990; 10:373–375 [G]

    174. Jensen HV, Andersen J: An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989; 79:89–93 [B]

    175. Montgomery SA, Roy D, Montgomery DB: The prevention of recurrent suicidal acts. Br J Clin Pharmacol 1983; 15(suppl 2):183S–188S [A]

    176. Pande AC, Birkett M, Fechner-Bates S, Haskett RF, Greden JF: Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996; 40:1017–1020 [A]

    177. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM: Behavioral dyscontrol in borderline patients treated with amitriptyline. Psychopharmacol Bull 1987; 23:177–181 [A]

    178. Shader RI, DiMascio A: Psychotropic Drug Side Effects. Baltimore, Williams and Wilkins, 1970 [G]

    179. Rifkin A, Levitan SJ, Galewski J, Klein DF: Emotionally unstable character disorder—a follow-up study, I: description of patients and outcome. Biol Psychiatry 1972; 4:65–79 [C]

    180. Rifkin A, Levitan SJ, Galewski J, Klein DF: Emotionally unstable character disorder—a follow-up study, II: prediction of outcome. Biol Psychiatry 1972; 4:81–88 [C]

    181. Shader RI, Jackson AH, Dodes LM: The antiaggressive effects of lithium in man. Psychopharmacologia 1974; 40:17–24 [G]

    182. LaWall JS, Wesselius CL: The use of lithium carbonate in borderline patients. J Psychiatr Treatment and Evaluation 1982; 4:265–267 [G]

    183. Pinto OC, Akiskal HS: Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51:333–343 [B]

    184. Wolf M, Grayden T, Carreon D, Cosgro M, Summers D, Leino R, Goldstein J, Kim S: Psychotherapy and buspirone in borderline patients, in 1990 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1990, p 244 [B]

    185. Winchel RM, Stanley M: Self-injurious behavior: a review of the behavior and biology of self-mutilation. Am J Psychiatry 1991; 148:306–317 [F]

    186. van der Kolk BA, Greenberg MS, Orr SP, Pitman RK: Endogenous opioids, stress induced analgesia, and posttraumatic stress disorder. Psychopharmacol Bull 1989; 25: 417–421 [F]

    187. Konicki PE, Schulz SC: Rationale for clinical trials of opiate antagonists in treating patients with personality disorders and self-injurious behavior. Psychopharmacol Bull 1989; 25:556–563 [E]

    188. McGee M: Cessation of self-mutilation in a patient with borderline personality disorder treated with naltrexone. J Clin Psychiatry 1997; 58:32–33 [E]

    189. Sonne S, Rubey R, Brady K, Malcolm R, Morris T: Naltrexone treatment of self-injurious thoughts and behaviors. J Nerv Ment Dis 1996; 184:192–195 [B]

    190. Roth AS, Ostroff RB, Hoffman RE: Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996; 57:233–237 [B]

    191. Russ M, Roth SD, Kakuma T, Harrison K, Hull JW: Pain perception in self-injurious borderline patients: naloxone effects. Biol Psychiatry 1994; 35:207–209 [B]

    192. Black DW, Bell S, Hulbert J, Nasrallah A: The importance of axis II in patients with major depression: a controlled study. J Affect Disord 1988; 14:115–122 [D]

    193. Black DW, Goldstein RB, Nasrallah A, Winokur G: The prediction of recovery using a multivariate model in 1471 depressed inpatients. Eur Arch Psychiatry Clin Neurosci 1991; 241:41–45 [E]

    194. Zimmerman M, Coryell W, Pfohl B, Corenthal C, Stangl D: ECT response in depressed patients with and without a DSM-III personality disorder. Am J Psychiatry 1986; 143: 1030–1032 [B]

    195. Pfohl B, Stangl D, Zimmerman M: The implications of DSM-III personality disorders for patients with major depression. J Affect Disord 1984; 7:309–318 [B]

    196. Casey P, Butler E: The effects of personality on response to ECT in major depression. J Personal Disord 1995; 9:134–142 [B]

    197. Casey P, Meagher D, Butler E: Personality, functioning, and recovery from major depression. J Nerv Ment Dis 1996; 184:240–245 [B]

    198. Blais MA, Matthews J, Schouten R, O’Keefe SM, Summergrad P: Stability and predictive value of self-report personality traits pre- and post-electroconvulsive therapy: a preliminary study. Compr Psychiatry 1998; 39:231–235 [B]

    This article is provided for educational purposes only. No profit comes from this article. The more exposure I feel this article gets, the less people with the BPD will suffer. Clinicians need this training. Consumers and families desperately need to be educated. I am deeply grateful to the researchers that provide us with valuable information in assisting us with treatment and etiology.

    [ Home ] [ BPD Bookstore ] [ Search BPD Today ] [ DSM IV Diagnosis ] [ Ask the Therapist ] [ Ask the Dr. Archives ] [ Therapist's Archives ] [ What's New? ] [ Articles ] [ BPD Research ] [ BPD Advocacy Program ] [ Borderlines Speak Out ] [ BPD Stories ] [ BPD Chat ] [ BPD Family Chat ] [ BPD Bulletin Board ] [ BPD Open Forum ] [ BPD Christian Board ] [ BPD Parents Board ] [ BPD Teenager Board ] [ Self Injury Board ] [ DBT Board ] [ Family Board ] [ Parents of BPD Board ] [ Children of BPD Board ] [ BPD Communities ] [ Family Section ] [ Membership Section ] [ Author Interviews ] [ Older BPDs  ] [ BPD Rages  ] [ Clinicians That Treat BPD ] [ Resources ] [ Links ] [ Email Volunteers ] [ Spiritual Support  ] [ Consumer Resources ] [ Clinicians ] [ Awards ] [ Webrings ] [ Contact Us ]